Rezolute, Inc. · NASDAQ:RZLT

Rezolute — AntriaBio — American Diabetes Association 75th Scientific Sessions 2015

12 slides from Rezolute's conference presentation, Jun 8, 2015

1. Slide 1: The in Vitro and in Vivo Pharmacology of AB101, a Potential Once-Weekly Basal Subcutaneous Insulin

   The in Vitro and in Vivo Pharmacology of AB101, a Potential Once-Weekly Basal Subcutaneous Insulin BRIAN K ROBERTS, XUEYAN WANG, MARY S ROSENDAHL, SANKARAM MANTRIPRAGADA, Louisville, CO 97-OR American Diabetes Association 75" Scientific Sessions® ele June 6, 2015 >

2. Slide 2: Forward-Looking Statements

   Forward-Looking Statements This presentation contains forward-looking statements about AntriaBio, Inc. (the “Company”). These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward- looking statements relate t

3. Slide 3: Disclosures

   Disclosures All authors are employees and stock option holders of AntriaBio, Inc., the sponsor/company developing AB101

4. Slide 4: AB101 Addresses an Unmet Need for a Longer-Acting Basal Insulin

   AB101 Addresses an Unmet Need for a Longer- Acting Basal Insulin + Barriers to adequate insulin utilization may include - Insulin/needle-averse patients - Safety concerns, including hypoglycemia - Weight gain + Alonger-acting basal insulin represents a convenient, effective, and safe treatment optio

5. Slide 5: AB101 is a Slow Release Microsphere Encapsulated Peg (5 kDa)-insulin

   4AB101 is a Slow Release Microsphere Encapsulated Peg (5 kDa)-insulin PEG+ native Ins soluble insulin insulin + PLGA = slow release microspheres 5 kDa PEG attached to the N-terminus of insulin’s B-Chain using site-specific amine End Result: 4B101 PEGylation. Drug dispersed evenly throughout microsph

6. Slide 6: Peginsulin (Drug Substance) Exhibits Receptor Binding Kinetics Predictive of Desired Pharmacology

   Peginsulin (Drug Substance) Exhibits Receptor Binding Kinetics Predictive of Desired Pharmacology with Low Mitogenic Potential Insulin and IGF-1 receptor binding kinetics Using Surface Plasmon Resonance (Biacore 3000) IGF-1 _ Insulin i Insulin Peginsulin Peginsulin ‘2 Association ““ Dissociation Ass

7. Slide 7: AB101 Single Dose SC Administration to Normal Rats Results in Slow Onset, Sustained PK-PD

   AB101 Single Dose SC Administration to Normal Rats Results in Slow Onset, Sustained PK-PD Serial Fasting Glucose and Insulin Measurements After a Single Dose of 37.5 mg/kg in Normal Sprague Dawley Rats (N=6) s2e88 Blood Glucose (mg/dl) Dose — Experiment #1_Glucose — Experiment #2_Glucose == Experime

8. Slide 8: AB101 Produces Peakless Pharmacology Over the Time-Action Duration of Currently Available Basal Insulins

   AB101 Produces Peakless Pharmacology Over the Time-Action Duration Associated with Currently Available Basal Insulins (24h) cy Ss Blood Glucose (mg/dl) s Serum Insulin (ng/ml) ° a o Days — Experiment #1_Glucose — Experiment #2_Glucose == Experiment #1_Ins == Experiment #2_Ins

9. Slide 9: AB101 Single Dose SC Administration to Normal Dogs Results in Slow Onset, Sustained PK-PD

   AB101 Single Dose SC Administration to Normal Dogs Results in Slow Onset, Sustained PK-PD Serial Fasting Glucose and Insulin Measurements After a Single Dose in Normal Beagle Dogs (N=3/dose group) * Non-fasted glucose or insulin & Insulin (ng/ml) — AB104 (10 mg/kg)_Glu = — AB104 (37.5 mg/kg)_Glu ==

10. Slide 10: Pharmacology Summary

    Pharmacology Summary Potency and activity are comparable to recombinant human insulin Slow onset, sustained insulin increases and corresponding glucose reductions over the course of ~1 week in 2 species (rats and dogs) No acute insulin release or glucose reduction observed Data support weekly dosing

11. Slide 11: How Does this Translate to the Treatment of Diabetes?

    How Does this Translate to the Treatment of Diabetes? + Inter-species homology of insulin/receptor predicts insulin activity in humans + No expected differences in activity in diabetes compared to non- diabetes (time-action profile or pharmacodynamics) + Pharmacology in dogs observed at predicted do

12. Slide 12: Acknowledgements

    Acknowledgements * AntriaBio, Inc. Scientists: - Aimee Stutts - James Vardas + Contract Research Labs: - ZenBio (CA) - 7% Wave Labs (MO) - High Quality Research Labs (CO) + Scientific/Clinical Advisory Board - Andrew R. Hoffman Philip Home C. Ronald Kahn Fredrick B. Kraemer Jerrold Olefsky

AntriaBio — American Diabetes Association 75th Scientific Sessions 2015 on 6ix